The Use of Lisdexamfetamine to Treat ADHD in a Patient with Stimulant (Methamphetamine) Use Disorder
- PMID: 37609571
- PMCID: PMC10442178
- DOI: 10.1155/2023/5574677
The Use of Lisdexamfetamine to Treat ADHD in a Patient with Stimulant (Methamphetamine) Use Disorder
Abstract
Introduction: The treatment of attention deficit hyperactivity disorder (ADHD) with stimulants among patients with stimulant use disorder carries concern for efficacy and exacerbation of addictive behaviors. Lisdexamfetamine is a unique stimulant used to treat ADHD with a lower abuse potential compared to other stimulants, as the medication is the only prodrug in its class. To our knowledge, there are no reports in the literature of the use of lisdexamfetamine to treat ADHD in patients with stimulant use disorder.
Methods: We present a 33-year-old male with a history of stimulant (methamphetamine) use disorder, who was found to have long-standing ADHD. The patient was treated with lisdexamfetamine 30 mg, which was increased and sustained at 40 mg.
Results: The patient reported significant improvement in focus, concentration, calmness, organization of thoughts, and less of a tendency to procrastinate. Additionally, he denied exacerbation of anxiety or sleep disturbances. He reported his cravings for stimulants were significantly decreased. After 2 months of treatment, he had moved out from his sober living facility, started a new job, and gained a promotion. He had no use of illicit substances, which was proven by routine urine drug screens.
Conclusion: Our patient's ADHD was successfully treated with lisdexamfetamine. Not only did the patient's ADHD symptoms improve, but his cravings for stimulants were relieved. ADHD is common among patients with stimulant use disorder. Patients with ADHD and stimulant use disorder should not necessarily forgo pharmacologic treatment with stimulants for concerns of abuse. Due to its unique pharmacokinetic profile, lisdexamfetamine is a feasible treatment for patients with ADHD and a history of stimulant use disorder.
Copyright © 2023 J. Levine and H. Swanson.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Similar articles
-
Lisdexamfetamine dimesylate: the first prodrug stimulant.Psychiatry (Edgmont). 2007 Aug;4(8):39-45. Psychiatry (Edgmont). 2007. PMID: 20532026 Free PMC article.
-
A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6. CNS Drugs. 2013. PMID: 23801529 Free PMC article. Clinical Trial.
-
Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.Curr Med Res Opin. 2020 Oct;36(10):1717-1735. doi: 10.1080/03007995.2020.1815002. Epub 2020 Sep 11. Curr Med Res Opin. 2020. PMID: 32845786
-
The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.Clin Ther. 2009 Jan;31(1):142-76. doi: 10.1016/j.clinthera.2009.01.015. Clin Ther. 2009. PMID: 19243715 Review.
-
Lisdexamfetamine for treatment of attention-deficit/hyperactivity disorder.Ann Pharmacother. 2009 Apr;43(4):669-76. doi: 10.1345/aph.1L521. Epub 2009 Mar 24. Ann Pharmacother. 2009. PMID: 19318601 Review.
Cited by
-
Amphetamines in child medicine: a review of ClinicalTrials.gov.Front Pharmacol. 2023 Oct 3;14:1280562. doi: 10.3389/fphar.2023.1280562. eCollection 2023. Front Pharmacol. 2023. PMID: 37854716 Free PMC article.
-
Emerging medications and pharmacological treatment approaches for substance use disorders.Pharmacol Biochem Behav. 2025 Mar;248:173952. doi: 10.1016/j.pbb.2024.173952. Epub 2024 Dec 22. Pharmacol Biochem Behav. 2025. PMID: 39719161 Free PMC article. Review.
References
-
- Cortese S., Adamo N., Del Giovane C., et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet Psychiatry . 2018;5(9):727–738. doi: 10.1016/S2215-0366(18)30269-4. - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources